
# Cancer bioinformatics: identification of diagnostic and prognostic biomarkers from gene expression data

Garrett Dancik
University of Colorado Denver
December 17, 2012

## Leading causes of death (2010)




Lifetime probability of developing cancer

**Males: 50%** 

Females: 33%


#### 2010 Estimated US Cancer Cases\*



<sup>\*</sup>Excludes basal and squamous cell skin cancers and in situ carcinomas except urinary bladder.

#### What is cancer?


#### Hallmarks of cancer



Hanahan and Weinberg. Cell 2011; 144(5):646–674.


## Cancer is a genetic disease


#### Central dogma of molecular biology



### Cancer is a genetic disease


#### Central dogma of molecular biology






#### Gene expression profiling by microarray

#### Central dogma of molecular biology



#### Biomarkers and personalized medicine

#### Gene expression profiles



#### Class comparison

- A,B: clinical variable or outcome
  - Tumor type
  - High risk vs. low risk (survival)
  - Responders vs. non-responders
- Classification of new samples:
  - Gene signature
  - Classification method:
    - KNN, SVM, PCA, NCC, etc.
- Diagnostic biomarker: a gene or gene signature that is predictive of a clinical variable (e.g., tumor grade)
- **Prognostic biomarker:** a gene or gene signature that is predictive of disease outcome (e.g., survival)

A framework to select clinically relevant cell lines by establishing their molecular similarity with patient tumors


### Background and motivation

- Cell lines as model systems in cancer
  - Characterization of molecular mechanisms of disease
  - Characterization of activity of therapeutic agents
  - High throughput drug discovery programs
- But....cell lines do not always represent patient tumors
  - Adaptation in culture
  - Cross-contamination
- In vitro (cell line) drug sensitivity often does not correlate with drug efficacy in patients

### Motivation and approach

- Objective: identify and select clinically relevant cell lines based on their gene expression profiles
  - Classify a panel of 36 bladder (BLA-36) cell lines
- Classification objectives
  - Tissue of origin (from 10 epithelial tumors)
  - Stage (NMI vs. MI)
  - Grade (high grade vs. low grade)
  - Disease specific survival (high vs. low risk)


## Spearman rank correlation classification method (SRCCM)




#### Tissue of origin classification

- Clinical relevance of tissue of origin
  - Chemotherapy and radiation therapy efficacy depends on tumor type (Kemp CJ, et al. *Cancer Res* 2001;61(1):327-332)
  - Metastatic site preference is tissue specific
- Do cell lines resemble their derived tissues
  - Previous studies: Only 57% of NCI-60 cell lines resemble presumed tissue of origin (Sandberg R, Ernberg I. PNAS 2005;102(6):2052-2057).
  - Survey of 500 leukemia-lymphoma cell lines finds 15%
     mislabeled (Drexler HG et al. *Leukemia*. 2003;17(2):416-426)


#### Tissue of origin classification



#### Grade classification




**Low grade**Well differentiated




vs. High gradevs. poorly differentiated

Dataset	SRCCM accuracy
Lindgren (LOOCV)	0.875
SC	0.813

#### Grade classification




**Low grade**Well differentiated




vs. High gradevs. poorly differentiated

Dataset	SRCCM accuracy
Lindgren (LOOCV)	0.875
SC	0.813
BLA-36	.571

Original tumor grades no longer correlate with survival; correlation is restored through cell line selection via SRCCM



Selection of the most clinically relevant cell lines by survival risk, grade, and tissue type



## Summary

- SRCCM algorithm for classification and cell line model selection
- BLA-36
  - Grade: accuracy < 60%, suggesting that many cell lines no longer resemble original tumors with respect to grade
  - Original tumor grade no longer correlates with survival; correlation is restored through SRCCM selection
- Software: Correlation classification method (CCM) <a href="http://cran.r-project.org/web/packages/CCM/index.html">http://cran.r-project.org/web/packages/CCM/index.html</a>

## Acknowledgements




- Theodorescu Lab
  - Dan Theodorescu, MD, PhD (PI)
  - Yuanbin Ru, PhD
  - Chuck Owens (lab technician)
- Funding: NIH CA075115.


## Thank You!

#### Cancer grade and staging

- Tumor grade
  - Normal vs. abnormal
  - Low vs. high grade
- Tumor stage
  - How far has the cancer spread
- Bladder cancer stages
  - Non-muscle invasive (NMI):Ta, T1
    - 5 year survival rate of ~ 90%
    - Progression rate of ~ 20%
  - Muscle invasive (MI): T2-T4
    - 5 year survival rate ~ 50%



#### Bladder cancer grade classification



#### **Presentation Tips**

- You are presenting your paper:
  - background, significance, objective, methods, results
- Almost every slide is a picture (or table)
  - —From the internet (with reference)
  - From another publication (with reference)
  - —From original research

### **Presentation Tips**

- Presentation is written out and practiced ahead of time
- You do NOT read off of the page
- Additional slides are included at the end
  - For results or background not presented do to time
  - To answer possible questions